Redpoint Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Redpoint Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,985	Closed	-$384K	–	614
2022 Q1	$384K	Buy	4,985 +394	+9%	+$33K	0.04%	497
2021 Q4	$406K	Hold	4,591	–	–	0.03%	500
2021 Q3	$355K	Hold	4,591	–	–	0.03%	531
2021 Q2	$383K	Hold	4,591	–	–	0.03%	522
2021 Q1	$347K	Hold	4,591	–	–	0.03%	536
2020 Q4	$403K	Hold	4,591	–	–	0.04%	413
2020 Q3	$349K	Sell	4,591 -366	-7%	-$37K	0.04%	439
2020 Q2	$611K	Buy	4,957 +1,182	+31%	+$117K	0.03%	413
2020 Q1	$319K	Hold	3,775	–	–	0.02%	453
2019 Q4	$319K	Hold	3,775	–	–	0.02%	508
2019 Q3	$254K	Buy	3,775 +642	+20%	+$49.4K	0.01%	528
2019 Q2	$268K	Hold	3,133	–	–	0.01%	530
2019 Q1	$278K	Hold	3,133	–	–	0.01%	523
2018 Q4	$267K	Hold	3,133	–	–	0.02%	504
2018 Q3	$304K	Hold	3,133	–	–	0.02%	503
2018 Q2	$295K	Hold	3,133	–	–	0.02%	462
2018 Q1	$254K	Hold	3,133	–	–	0.01%	477
2017 Q4	$279K	Buy	+3,133	New	+$272K	0.02%	466

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redpoint Investment Management's BMRN Position: Q2 2022 in Review

Redpoint Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 4,985 shares — an estimated $384K sold.

Redpoint Investment Management first reported a position in BMRN in Q4 2017 and held it in 18 quarters. The position peaked at $611K in Q2 2020. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Redpoint Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Redpoint Investment Management sold 4,985 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $384K.
Redpoint Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 18 quarters.
Redpoint Investment Management's BioMarin Pharmaceuticals position peaked at $611K in Q2 2020.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Redpoint Investment Management's 13F filing for Q2 2022, filed 8 Jul 2022.